María del Rosario
García Campelo

Foto de María del Rosario

Foto de Centre François Baclesse

Centre François Baclesse

Esch-sur-Alzette, Luxemburgo

Publicacións en colaboración con investigadores/as de Centre François Baclesse (4)

2023

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Scientific Reports

2015

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5

2014

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-Mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial
Clinical Cancer Research, Vol. 20, Núm. 7, pp. 2001-2010

2012

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

Proxecto CRIS desenvolto en colaboración coa Fundación Dialnet (Universidad de La Rioja)